2. Signaling Pathways
  3. Apoptosis
  4. c-Myc

c-Myc

Myc

c-Myc

Related Products

PDF 0.13 MB

The transcription factor c-Myc is a member of the basic helix-loop-helix leucinezipper (bHLHZip) protein family. The target genes of the c-MYC protein participate in different cellular functions, including cell cycle, survival, protein synthesis, cell adhesion, and micro-RNA expression. c-Myc is also one of the four factors used in reprogramming somatic cells to induce pluripotent stem (iPS) cells and is implicated in maintaining cancer stem-like cells (CSCs). Most biological functions of c-Myc require heterodimerization with its activation partner Max.

c-Myc is also part of a dynamic network whose members interact selectively with one another and with various transcriptional coregulators and histone-modifying enzymes. Deregulated expression of c-MYC caused by gene amplification, retroviral insertion, or chromosomal translocation is associated with tumorigenesis. c-Myc has been identified as a highly promising target for cancer therapy.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-12702
    10058-F4
    		Inhibitor 99.77%
    10058-F4 is a c-Myc inhibitor that prevents c-Myc-Max dimerization and transactivation of c-Myc target gene expression.
    10058-F4
  • HY-17381
    Idarubicin hydrochloride
    		Inhibitor 99.94%
    Idarubicin hydrochloride is an anthracycline antileukemic agent. It inhibits the topoisomerase II interfering with the replication of DNA and RNA transcription. Idarubicin hydrochloride inhibits the growth of bacteria and yeasts.
    Idarubicin hydrochloride
  • HY-16291
    APTO-253
    		Inhibitor 98.81%
    APTO-253 (LOR-253) is a small molecule that inhibits c-Myc expression, stabilizes G-quadruplex DNA, and induces cell cycle arrest and apoptosis in acute myeloid leukemia cells. APTO-253 mediates anticancer activity through induction of the Krüppel-like factor 4 (KLF4) tumor suppressor. APTO-253 has antiarthritic activity.
    APTO-253
  • HY-19735
    KJ Pyr 9
    		Inhibitor 99.62%
    KJ Pyr 9 is an inhibitor of MYC with a Kd of 6.5 nM in in vitro assay.
    KJ Pyr 9
  • HY-N2302
    Fucoxanthin
    		99.47%
    Fucoxanthin (all-trans-Fucoxanthin) is a marine carotenoid and shows anti-obesity, anti-diabetic, anti-oxidant, anti-inflammatory and anticancer activities.
    Fucoxanthin
  • HY-162796
    TS-2
    TS-2 is a fluorescent ligand of c-Myc G4 with anticancer activity. TS-2 inhibits the growth of cancer cells and induces apoptosis of cancer cells by targeting the c-MYC oncogene promoter G4, causing transcriptional repression of the c-Myc oncogene.
    TS-2
  • HY-N0330R
    Momordin Ic (Standard)
    		Inhibitor
    Momordin Ic (Standard) is the analytical standard of Momordin Ic. This product is intended for research and analytical applications. Momordin Ic is an orally active triterpenoid saponin that can be isolated from Kochia scoparia. It is also a SUMO specific protease 1 (SENP1) inhibitor, SENP1/c-MYC signaling pathway inhibitor, and apoptosis inducer. Momordin Ic induces autophagy and apoptosis in liver cancer cells through the PI3K/Akt and MAPK signaling pathways mediated by reactive oxygen species. Momordin Ic has the ability to control glucose induced blood glucose elevation, inhibit gastric emptying, resist rheumatoid arthritis, reduce CCl4 (HY-Y0298) induced hepatotoxicity and anti-tumor activity.
    Momordin Ic (Standard)
  • HY-16291A
    APTO-253 hydrochloride
    		Inhibitor
    APTO-253?(LOR-253) hydrochloride is a small molecule that inhibits c-Myc expression, stabilizes G-quadruplex DNA and induces cell cycle arrest and apoptosis in acute myeloid leukemia cells. APTO-253?hydrochloride mediates anticancer activity via induction of Kruppel-like factor 4?(KLF4)?tumor suppressor. APTO-253?hydrochloride exhibits antiarthritic activity.
    APTO-253 hydrochloride
  • HY-124675
    MYCMI-6
    		Inhibitor 98.14%
    MYCMI-6 (NSC354961) is a potent and selective endogenous MYC:MAX protein interactions inhibitor. MYCMI-6 blocks MYC-driven transcription and binds selectively to the MYC bHLHZip domain with a Kd of 1.6 μM. MYCMI-6 inhibits tumor cell growth in a MYC-dependent manner (IC50<0.5 μM). MYCMI-6 is not cytotoxic to normal human cells. MYCMI-6 induces apoptosis.
    MYCMI-6
  • HY-134761
    EN4
    		Inhibitor
    EN4 is a covalent ligand that targets cysteine 171 (C171) of MYC. EN4 is selective for c-MYC over N-MYC and L-MYC. EN4 inhibits MYC transcriptional activity, downregulates MYC targets, and impairs tumorigenesis.
    EN4
  • HY-N0330
    Momordin Ic
    		Inhibitor 99.71%
    Momordin Ic is an orally active triterpenoid saponin that can be isolated from Kochia scoparia. It is also a SUMO specific protease 1 (SENP1) inhibitor, SENP1/c-MYC signaling pathway inhibitor, and apoptosis inducer. Momordin Ic induces autophagy and apoptosis in liver cancer cells through the PI3K/Akt and MAPK signaling pathways mediated by reactive oxygen species. Momordin Ic has the ability to control glucose induced blood glucose elevation, inhibit gastric emptying, resist rheumatoid arthritis, reduce CCl4 (HY-Y0298) induced hepatotoxicity and anti-tumor activity.
    Momordin Ic
  • HY-129600
    MYCi361
    		Inhibitor 99.85%
    MYCi361 (NUCC-0196361) is a MYC inhibitor with the Kd of 3.2 μM for binding to MYC. MYCi361 (NUCC-0196361) suppresses tumor growth and enhances anti-PD1 immunotherapy.
    MYCi361
  • HY-100996
    10074-G5
    		Inhibitor 98.11%
    10074-G5 is an inhibitor of c-Myc-Max dimerization with an IC50 of 146 μM.
    10074-G5
  • HY-100669
    Mycro 3
    		Inhibitor 98.11%
    Mycro 3 is an orally active, potent and selective inhibitor of Myc-associated factor X (MAX) dimerization. Mycro 3 also inhibit DNA binding of c-Myc. Mycro 3 could be used for the research of pancreatic cancer.
    Mycro 3
  • HY-145898
    WBC100
    		Inhibitor
    WBC100 (14-D-Valine-TPL) is a potent, selective, and orally active c-Myc molecule glue degrader. WBC100 is a c-Myc degrader and targets ubiquitin E3 ligase CHIP mediated 26S proteasome pathway. WBC100 is used for c-Myc overexpressing tumors research.
    WBC100
  • HY-124447
    BTYNB
    		Inhibitor ≥98.0%
    BTYNB is a potent and selective inhibitor of IMP1 binding to c-Myc mRNA (IC50=5 μM). BTYNB exhibits selectivity and effectiveness against IMP1-postive cancer cell lines. BTYNB can be used for cancer research.
    BTYNB
  • HY-122683
    sAJM589
    		Inhibitor 98.34%
    sAJM589 is a Myc inhibitor which potently disrupts the Myc-Max heterodimer with an IC50 of 1.8 μM.
    sAJM589
  • HY-N0704
    Agrimol B
    		Inhibitor 99.75%
    Agrimol B, a polyphenol, is an orally active and potent SIRT1 activator. Agrimol B shows anti-adipogenic and anticancer activity. Agrimol B shows antibacterial activity against plant pathogens. Agrimol B dramatically inhibits 3T3-L1 adipocyte differentiation by reducing PPARγ, C/EBPα, FAS, UCP-1, and apoE expression. The action of Agrimol B on the cancer cells is likely derived from its effect on c-MYC, SKP2 and p27.
    Agrimol B
  • HY-N0316
    Mollugin
    		Inhibitor 99.48%
    Mollugin is an orally active and potent NF-κB inhibitor. Mollugin induces S-phase arrest of HepG2 cells, and increased intracellular reactive oxygen species (ROS) levels. Mollugin induces DNA damage in HepG2 cells, as well as an increase in the expression of p-H2AX. Mollugin shows anti-cancer effect by inhibiting TNF-α-induced NF-κB activation. Mollugin enhances the osteogenic action of BMP-2 (bone morphogenetic protein 2) via the p38-Smad signaling pathway.
    Mollugin
  • HY-12703
    KSI-3716
    		Inhibitor 98.94%
    KSI-3716 is a potent c-Myc inhibitor that blocks c-MYC/MAX binding to target gene promoters. KSI-3716 is an effective intravesical chemotherapy agent for bladder cancer.
    KSI-3716
Cat. No. Product Name / Synonyms Application Reactivity